INSUlin Regimens and VASCular Functions (INSUVASC)
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Insulin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Insulin Therapy, Vago-sympathetic activity, arterial stiffness, endothelial function
Eligibility Criteria
Inclusion Criteria:
- Consent patient
- Adults from 30 to 72 years old
- type 2 diabetic patients for at least 1 year
- able to self measure capillary blood glucose
- body mass index 20-37 kg/m²,
- HbA1c 7.1-12% under Metformin and SULFUNYREAS therapy for at least 2 months
- anti-hypertensive treatment or dyslipidemic treatment unchanged for 3 months
Exclusion criteria:
- pregnancy
- other antidiabetic medication in the previous 2 months,
- anti-hypertensive or lipid-lowering therapies having been changed in the previous 2 months,
- insulin allergy,
- uncontrolled preproliferative or proliferative diabetic retinopathy
- uncontrolled hypertension
- renal failure(creatinin clearance <40 ml/min)
- hepatocellular deficiency (prothrombin time <70%)
- anemia
- peripheral occlusive arterial disease
- cardiac arrhythmia
Sites / Locations
- Jean Verdier hospital, Department of Endocrinology-Diabetology-Nutrition
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
detemir
aspart
detemir and aspart
Arm Description
Insulin detemir at dinner or bedtime
Insulin aspart before each meal
Outcomes
Primary Outcome Measures
Vago-sympathetic activity, arterial stiffness, endothelial function
Secondary Outcome Measures
Full Information
NCT ID
NCT01022658
First Posted
November 30, 2009
Last Updated
February 20, 2013
Sponsor
Assistance Publique - Hôpitaux de Paris
1. Study Identification
Unique Protocol Identification Number
NCT01022658
Brief Title
INSUlin Regimens and VASCular Functions
Acronym
INSUVASC
Official Title
Effects of Different Insulin Regimens on Artery Compliance, Endothelium Function and Autonomic Cardiac Function in Patients With Poorly Controlled Type 2 Diabetes: a Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
February 2013
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
July 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Vago-sympathetic activity, arterial stiffness and endothelial function are integrators of cardiovascular risk. The aim of this pilot study is, in type 2 diabetic patients now requiring insulin, to compare the effects of improving glycemic control on these parameters with 3 different insulin regimens which will act especially at fasting or in post-prandial periods or both. Non invasive explorations will be performed before randomization and after 4 to 5 weeks of insulin therapy, at fasting and each hour after a standardized breakfast.
Detailed Description
Vago-sympathetic activity, arterial stiffness and endothelial function are integrators of cardiovascular risk. The effect of controlling fasting or post-prandial blood glucose or both on these parameters has not been studied in type 2 diabetic patients.
The aim of this pilot study is to compare the effects of improving fasting or post-prandial blood glucose glycemic control or both with 3 different insulin regimens for 4 to 5 weeks, on vago-sympathetic activity, arterial stiffness and endothelial function.
Patients will be recruited in the department of Endocrinology-Diabetology-Nutrition of Jean VERDIER hospital, AP-HP, and the department of Endocrinology and Metabolism of AVICENNE hospital, BOBIGNY, AP-HP, France. After an half day of cardiovascular explorations, 42 patients will be randomized in 3 groups determining their treatment for the following 4-5 weeks : insulin therapy with detemir at dinner or bed time, or with aspart at each meal, or with both of them.
Investigations will be performed in the morning 1) at the time of randomisation and 2) 4-5 weeks after the beginning of insulin therapy. We will evaluate at fasting and each hour after a standardized breakfast biological and metabolic parameters, arterial stiffness, endothelial function and nervous autonomic system with non-invasive devices: Sphygmocor®, Finapres®, laser-doppler et Endopat2000®. Body composition will be evaluated with impedance maestri and BodPod®.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Insulin Therapy, Vago-sympathetic activity, arterial stiffness, endothelial function
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
42 (Actual)
8. Arms, Groups, and Interventions
Arm Title
detemir
Arm Type
Active Comparator
Arm Description
Insulin detemir at dinner or bedtime
Arm Title
aspart
Arm Type
Active Comparator
Arm Description
Insulin aspart before each meal
Arm Title
detemir and aspart
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Insulin
Other Intervention Name(s)
LEVEMIR, NOVORAPID
Intervention Description
For diabetes treatment: metformin continued with insulin (according to arms)
Primary Outcome Measure Information:
Title
Vago-sympathetic activity, arterial stiffness, endothelial function
Time Frame
4-5 Weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
72 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Consent patient
Adults from 30 to 72 years old
type 2 diabetic patients for at least 1 year
able to self measure capillary blood glucose
body mass index 20-37 kg/m²,
HbA1c 7.1-12% under Metformin and SULFUNYREAS therapy for at least 2 months
anti-hypertensive treatment or dyslipidemic treatment unchanged for 3 months
Exclusion criteria:
pregnancy
other antidiabetic medication in the previous 2 months,
anti-hypertensive or lipid-lowering therapies having been changed in the previous 2 months,
insulin allergy,
uncontrolled preproliferative or proliferative diabetic retinopathy
uncontrolled hypertension
renal failure(creatinin clearance <40 ml/min)
hepatocellular deficiency (prothrombin time <70%)
anemia
peripheral occlusive arterial disease
cardiac arrhythmia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul Valensi, Pr
Organizational Affiliation
CHU Jean VERDIER
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Emmanuel Cosson, MD, PhD
Organizational Affiliation
CHU-Jean Verdier
Official's Role
Study Chair
Facility Information:
Facility Name
Jean Verdier hospital, Department of Endocrinology-Diabetology-Nutrition
City
Bondy
ZIP/Postal Code
93140
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
17375404
Citation
Nitenberg A, Cosson E, Pham I. Postprandial endothelial dysfunction: role of glucose, lipids and insulin. Diabetes Metab. 2006 Sep;32 Spec No2:2S28-33. doi: 10.1016/s1262-3636(06)70482-7.
Results Reference
background
PubMed Identifier
9614623
Citation
Albertini JP, Valensi P, Lormeau B, Aurousseau MH, Ferriere F, Attali JR, Gattegno L. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes Care. 1998 Jun;21(6):1008-13. doi: 10.2337/diacare.21.6.1008.
Results Reference
background
PubMed Identifier
17375406
Citation
Valensi P, Cosson E. Hemodynamic changes in postprandial state. Diabetes Metab. 2006 Sep;32 Spec No2:2S37-41. doi: 10.1016/s1262-3636(06)70484-0.
Results Reference
background
PubMed Identifier
7735337
Citation
Valensi P, Thi BN, Lormeau B, Paries J, Attali JR. Cardiac autonomic function in obese patients. Int J Obes Relat Metab Disord. 1995 Feb;19(2):113-8.
Results Reference
background
PubMed Identifier
15506059
Citation
Dabire H, Brahimi M, Hadj-Brahim F, Le Clesiau H, Attali JR, Valensi P. [Role of vagosympathetic balance in obesity-induced hypertension]. Arch Mal Coeur Vaiss. 2004 Jul-Aug;97(7-8):749-52. French.
Results Reference
background
PubMed Identifier
12870154
Citation
Valensi P, Paries J, Attali JR; French Group for Research and Study of Diabetic Neuropathy. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications--the French multicenter study. Metabolism. 2003 Jul;52(7):815-20. doi: 10.1016/s0026-0495(03)00095-7.
Results Reference
background
PubMed Identifier
16154426
Citation
Valensi P, Paries J, Lormeau B, Attia S, Attali JR. Influence of nutrients on cardiac autonomic function in nondiabetic overweight subjects. Metabolism. 2005 Oct;54(10):1290-6. doi: 10.1016/j.metabol.2005.04.016.
Results Reference
background
PubMed Identifier
12208795
Citation
Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation. 2002 Sep 3;106(10):1211-8. doi: 10.1161/01.cir.0000027569.76671.a8.
Results Reference
background
PubMed Identifier
9054462
Citation
Valensi P, Smagghue O, Paries J, Velayoudon P, Nguyen TN, Attali JR. Peripheral vasoconstrictor responses to sympathetic activation in diabetic patients: relationship with rheological disorders. Metabolism. 1997 Mar;46(3):235-41. doi: 10.1016/s0026-0495(97)90246-8.
Results Reference
background
PubMed Identifier
10831169
Citation
Valensi P, Smagghue O, Paries J, Velayoudon P, Lormeau B, Attali JR. Impairment of skin vasoconstrictive response to sympathetic activation in obese patients: influence of rheological disorders. Metabolism. 2000 May;49(5):600-6. doi: 10.1016/s0026-0495(00)80034-7.
Results Reference
background
PubMed Identifier
9404427
Citation
Sibony-Prat J, Paries J, Chabert M, Attali JR, Valensi P. [Alteration of cardiovascular vagosympathetic control evaluated by spectral analysis of variations of heart rate and blood pressure in obesity]. Arch Mal Coeur Vaiss. 1997 Aug;90(8):1155-8. French.
Results Reference
background
PubMed Identifier
28954218
Citation
Fysekidis M, Cosson E, Takbou K, Sutton A, Charnaux N, Banu I, Vicaut E, Valensi P. Effects of insulin analogs as an add-on to metformin on cutaneous microcirculation in type 2 diabetic patients. Microvasc Res. 2018 Mar;116:6-14. doi: 10.1016/j.mvr.2017.09.005. Epub 2017 Sep 24.
Results Reference
derived
Learn more about this trial
INSUlin Regimens and VASCular Functions
We'll reach out to this number within 24 hrs